Scleroderma and Raynauds Phenomenon

Our research in scleroderma related diseases begin in 1989 with the recognition and description of the Eosinophilia Myalgia Syndrome and its relationship to epidemic Eosinophilic Fasciitis. 

West Michigan Rheumatology was one of the original investigational sites for the Scleroderma Clinical Trials Consortium beginning in 1994 with the landmark  "High dose, Low dose d-Penicillamine Trial".   

We have continued this thread of investigation by evaluating the validity of the Rodnan Scleroderma Skin Score (a primary outcome in generalized scleroderma studies) and the Raynaud's  Condition Score (the primary outcome for all raynauds clinical  trials).  We have conducted a number of investigations of potential treatments including "d-Penicillamine",  "Relaxin" for generalized, diffuse scleroderma,  "dasatimib" for pulmonary fibrosis in diffuse scleroderma, and "scleroderma treatment strategies.  In 2015 - 2017 we were the second largest center iCytori STAR StudyThis evaluated the effectiveness of injection of autologously harvested fat stem cells into the fingers of patients with scleroderma related hand contractures.  In 2016-8 we participated in the FocuSSCed StudyThis evaluated subcutaneous Actemra, an FDA approved treatment for RA, in early diffuse scleroderma. 

We have also participated in the design and conduct of several studies of potential therapies for raynauds phenomenon:   "oral iloprost", "Vascana", and "PF-00489791”.   


Want to learn more? 

We have only shared a brief overview of our current research projects.  If you are interested in learning more about participation, please contact our research coordinator via email using the form below. She would be happy to provide further information on specific studies via email and follow up with you on the phone to answer your questions about the details of participation.   You may also reach her by calling 616.459.8088.











© 2019 West Michigan Rheumatology, PLLC  1155 East Paris SE, Suite 100  Grand Rapids, MI 49546   Voice 616.459.8088    FAX 616.459.8312